TrialThe Lancet. Oncology2014

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Jason R Westin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.